Cargando…

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy

BACKGROUND: Pancreatic carcinoma is a significant cause of cancer-related death in developed countries. As the level of circulating endothelial cells (CECs) is known to increase in response to various cancers, we investigated the predictive potential of CEC levels and the association of these levels...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, Shunsuke, Ueno, Hideki, Hashimoto, Jun, Morizane, Chigusa, Koizumi, Fumiaki, Okusaka, Takuji, Tamura, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437212/ https://www.ncbi.nlm.nih.gov/pubmed/22731825 http://dx.doi.org/10.1186/1471-2407-12-268

Ejemplares similares

A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2014)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma
por: Kondo, Shunsuke, et al.
Publicado: (2018)

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study
por: Iizumi, Sakura, et al.
Publicado: (2019)

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial
por: Terazawa, Tetsuji, et al.
Publicado: (2014)

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis
por: Mayahara, Hiroshi, et al.
Publicado: (2012)

Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma
por: Kondo, S, et al.
Publicado: (2013)

Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
por: Takai, Erina, et al.
Publicado: (2015)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2018)

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
por: Hagihara, Atsushi, et al.
Publicado: (2014)

Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile
por: Hijioka, Susumu, et al.
Publicado: (2023)

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients
por: Ueno, H, et al.
Publicado: (2009)

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
por: Ito, Tetsuhide, et al.
Publicado: (2013)

The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

Author Correction: The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
por: Sakamoto, Yasunari, et al.
Publicado: (2019)

Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017)

Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
por: Aoki, Taku, et al.
Publicado: (2014)

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer
por: Terashima, Takeshi, et al.
Publicado: (2019)

Endoscopic ultrasound‐guided choledochoduodenostomy without fistula dilation using a stent with a 5.9‐Fr delivery system: Comparison to a conventional procedure with fistula dilation
por: Koga, Takehiko, et al.
Publicado: (2021)

Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
por: Yamaguchi, Tomohiro, et al.
Publicado: (2014)

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease
por: Udagawa, Chihiro, et al.
Publicado: (2019)

Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial
por: Furuse, Junji, et al.
Publicado: (2022)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Comparison of the hybrid and partial stent-in-stent method for endoscopic three-segment drainage for unresectable malignant hilar biliary obstruction
por: Yoshinari, Motohiro, et al.
Publicado: (2023)

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
por: Okusaka, Takuji, et al.
Publicado: (2023)

Comparison of 6-mm and 10-mm-diameter, fully-covered, self-expandable metallic stents for distal malignant biliary obstruction
por: Harai, Shota, et al.
Publicado: (2023)

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_ouo2dj8mam96l5b7sjbrd89rna